694 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
AstraZeneca Stock Upgraded: What You Need to Know https://www.fool.com/investing/2017/09/22/astrazeneca-stock-upgraded-what-you-need-to-know.aspx?source=iedfolrf0000001 Sep 22, 2017 - Bernstein sees opportunity in a buyout target.
1 Stock for General Electric Shareholders Now That Buffett Has Sold https://www.fool.com/investing/2017/09/12/1-stock-for-ge-shareholders-now-that-buffett-has-s.aspx?source=iedfolrf0000001 Sep 12, 2017 - Berkshire Hathaway sold GE, but there's an even better stock for those who want to get in on the ground floor of 21st-century manufacturing.
Here's Why Novo Nordisk A/S Gained 12% in August https://www.fool.com/investing/2017/09/06/heres-why-novo-nordisk-as-gained-12-in-august.aspx?source=iedfolrf0000001 Sep 06, 2017 - Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.
Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer http://www.zacks.com/stock/news/274787/mercks-mrk-keytruda-gets-eu-approval-for-bladder-cancer?cid=CS-ZC-FT-274787 Sep 06, 2017 - Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August https://www.fool.com/investing/2017/09/05/the-key-reason-incyte-corporation-added-850-millio.aspx?source=iedfolrf0000001 Sep 05, 2017 - An update on bariticinib's review timeline has Wall Street rightly excited.
Better Buy: Eli Lilly and Company vs. Pfizer Inc. https://www.fool.com/investing/2017/09/01/better-buy-eli-lilly-and-company-vs-pfizer.aspx?source=iedfolrf0000001 Sep 01, 2017 - How do Eli Lilly and Pfizer fare in a head-to-head matchup between the two big pharma stocks?
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected http://www.zacks.com/stock/news/274168/lilly-incyte-to-re-file-baricitinib-nda-faster-than-expected?cid=CS-ZC-FT-274168 Aug 31, 2017 - Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.
3 Most Promising Cancer Drugs in Late-Stage Development https://www.fool.com/investing/2017/08/22/3-most-promising-cancer-drugs-in-late-stage-develo.aspx?source=iedfolrf0000001 Aug 22, 2017 - Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates.
Here's Why Array BioPharma Inc. Fell 13.7% in July https://www.fool.com/investing/2017/08/07/heres-why-array-biopharma-inc-fell-137-in-may.aspx?source=iedfolrf0000001 Aug 07, 2017 - Despite sharing upbeat news, shares of the clinical-stage biotech fell by double-digits.
Q2 Earnings Fail to Impress Pharma ETF http://www.zacks.com/stock/news/271001/q2-earnings-fail-to-impress-pharma-etf?cid=CS-ZC-FT-271001 Aug 07, 2017 - The string of earnings beat failed to boost pharma ETFs.

Pages: 1...5152535455565758596061...70

<<<Page 56>